Circulating SARS-CoV-2 variants B.1.1.7, 501Y.V2, and P.1 have gained ability to utilize rat and mouse Ace2 and altered in vitro sensitivity to neutralizing antibodies and ACE2-Ig

Here, we first investigated cross-species receptor usage of multiple SARS-CoV-2 variants that emerged during the pandemic.  More...

NERVTAG: there is a realistic possibility that infection with VOC B117 is associated with an increased risk of death compared to infection with non-VOC viruses

“Several new analyses are however consistent in reporting increased disease severity in people infected with VOC B.1.1.7 compared to people infected with non-VOC virusvariants.”  More...